Obesity ETFs to Gain as Novo's CagriSema Shows 25% Weight LossZacks Investment Research · Oct 21, 2026
Bet on This New GLP-1 ETF to Gain Exposure to a Booming MarketZacks Investment Research · Oct 21, 2026
From Laggard to Leader: The Surprising Comeback of HealthcareETF Trends · Oct 13, 2026
Lilly vs. Novo: Inside the Milan EASD Showdown and the ETFs Poised to WinZacks Investment Research · Oct 1, 2026
Who Are You Calling Passive? Many Index ETFs Dynamically Rebalanced in SeptemberETF Trends · Sep 28, 2026
NTHM's Index Rebalance Puts Thematic Rotation to WorkETF Trends · Sep 25, 2026The Amplify Weight Loss Drug & Treatment ETF (THNR) offers investors a way to access international firms poised to benefit financially from advancements in weight management pharmaceuticals. Its primary objective is to mirror the investment performance (before any fees or expenses) of the VettaFi Weight Loss Drug & Treatment Index.